secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001493152-24-018418
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics Q1 net loss $9.3M ($0.31/share), revenue $0.5M, down 17% YoY
---------------------------------------------------------------------------

- Revenue $0.5M ($0.3M product, $0.2M grant) vs $0.6M in Q1 2023.
- Operating loss $10.3M, net loss $9.3M, vs $10.0M and $5.8M prior year.
- Adjusted EBITDA loss $8.4M, up from $7.2M; cash & securities $50.0M.
- Appointed four new executives: President Richard Abbott, COO, CTO, CCO.
- Opened new manufacturing facility in Salt Lake; plans 510(k) submission for PCR Pro and COVID-19 test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315224018418/0001493152-24-018418-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315224018418/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018418

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer